Deprescribing in older patients with hyperpolypharmacy: a cluster-randomised trial in primary care.

Background Polypharmacy increases the risk of adverse drug events and potentially preventable hospital admissions. Deprescribing may reduce medication-related harm, and a clinical medication review (CMR) provides an opportunity to support this. Objective To investigate the effect of a deprescribing-...

Full description

Bibliographic Details
Published in:Age & Ageing Vol. 55; no. 7; pp. 1 - 13
Main Authors: Baas, Gert, Heringa, Mette, Verdoorn, Sanne, Kwint, Henk-Frans, Badawy, Eman, Gussekloo, Jacobijn, Burgers, Jako, Denig, Petra, Bouvy, Marcel L
Format: Article
Published: Oxford University Press / USA Jul2026
Subjects:
Online Access:View this record in EBSCOhost
Description
Summary:Background Polypharmacy increases the risk of adverse drug events and potentially preventable hospital admissions. Deprescribing may reduce medication-related harm, and a clinical medication review (CMR) provides an opportunity to support this. Objective To investigate the effect of a deprescribing-focused CMR by trained pharmacists on the number of reduced and stopped medications among patients aged ≥75 years with hyperpolypharmacy using multidose-drug-dispensing (MDD)-systems. Methods In this cluster-randomised controlled trial, pharmacists were trained to perform a deprescribing-focused CMR, while control pharmacies provided usual care. Eligible patients were aged ≥75 years, had hyperpolypharmacy and used MDD. Dispensing data were used to determine the number of reduced and stopped medications per patient after 6 months (primary outcome). Secondary outcomes were: total number of medications, health problems and quality-of-life (EQ-5D-5L, EQ-VAS). A generalised linear mixed model was used for the primary outcome. Results A total of 318 patients from 58 pharmacies were enrolled (155 intervention, 163 control). At 6 months, patients in the intervention group had significantly more medications deprescribed than those in the control group (mean 2.5 vs. 1.7 per patient; mean difference 0.79, 95% CI 0.29–1.28; P  = .002). There was no significant between-group difference in the total number of medications at 6 months (intervention −0.30 vs. control +0.12; P  = .108). No significant differences were observed in health problems or quality-of-life. Conclusion Deprescribing-focused CMRs by trained pharmacists successfully increased reduction and stopping of medications in older patients with hyperpolypharmacy using MDD-systems, while no changes in health problems or health-related quality of life could be observed over 6 months.